TY - JOUR
T1 - Genetics of common cerebral small vessel disease
AU - Bordes, Constance
AU - Sargurupremraj, Muralidharan
AU - Mishra, Aniket
AU - Debette, Stéphanie
N1 - Publisher Copyright:
© 2022, Springer Nature Limited.
PY - 2022/2
Y1 - 2022/2
N2 - Cerebral small vessel disease (cSVD) is a leading cause of ischaemic and haemorrhagic stroke and a major contributor to dementia. Covert cSVD, which is detectable with brain MRI but does not manifest as clinical stroke, is highly prevalent in the general population, particularly with increasing age. Advances in technologies and collaborative work have led to substantial progress in the identification of common genetic variants that are associated with cSVD-related stroke (ischaemic and haemorrhagic) and MRI-defined covert cSVD. In this Review, we provide an overview of collaborative studies — mostly genome-wide association studies (GWAS) — that have identified >50 independent genetic loci associated with the risk of cSVD. We describe how these associations have provided novel insights into the biological mechanisms involved in cSVD, revealed patterns of shared genetic variation across cSVD traits, and shed new light on the continuum between rare, monogenic and common, multifactorial cSVD. We consider how GWAS summary statistics have been leveraged for Mendelian randomization studies to explore causal pathways in cSVD and provide genetic evidence for drug effects, and how the combination of findings from GWAS with gene expression resources and drug target databases has enabled identification of putative causal genes and provided proof-of-concept for drug repositioning potential. We also discuss opportunities for polygenic risk prediction, multi-ancestry approaches and integration with other omics data.
AB - Cerebral small vessel disease (cSVD) is a leading cause of ischaemic and haemorrhagic stroke and a major contributor to dementia. Covert cSVD, which is detectable with brain MRI but does not manifest as clinical stroke, is highly prevalent in the general population, particularly with increasing age. Advances in technologies and collaborative work have led to substantial progress in the identification of common genetic variants that are associated with cSVD-related stroke (ischaemic and haemorrhagic) and MRI-defined covert cSVD. In this Review, we provide an overview of collaborative studies — mostly genome-wide association studies (GWAS) — that have identified >50 independent genetic loci associated with the risk of cSVD. We describe how these associations have provided novel insights into the biological mechanisms involved in cSVD, revealed patterns of shared genetic variation across cSVD traits, and shed new light on the continuum between rare, monogenic and common, multifactorial cSVD. We consider how GWAS summary statistics have been leveraged for Mendelian randomization studies to explore causal pathways in cSVD and provide genetic evidence for drug effects, and how the combination of findings from GWAS with gene expression resources and drug target databases has enabled identification of putative causal genes and provided proof-of-concept for drug repositioning potential. We also discuss opportunities for polygenic risk prediction, multi-ancestry approaches and integration with other omics data.
UR - http://www.scopus.com/inward/record.url?scp=85122304094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122304094&partnerID=8YFLogxK
U2 - 10.1038/s41582-021-00592-8
DO - 10.1038/s41582-021-00592-8
M3 - Review article
C2 - 34987231
AN - SCOPUS:85122304094
SN - 1759-4758
VL - 18
SP - 84
EP - 101
JO - Nature Reviews Neurology
JF - Nature Reviews Neurology
IS - 2
ER -